GLP-1受容体作動薬市場：薬剤クラス別、薬剤タイプ別、投与経路別、用途別、流通チャネル別-2025-2030年の世界予測

GLP-1受容体作動薬市場は、2024年には403億1,000万米ドルとなり、2025年には455億9,000万米ドル、CAGR13.36%で成長し、2030年には855億5,000万米ドルに達すると予測されています。

GLP-1受容体作動薬市場は、科学的イノベーションと急速に進化するヘルスケアが出会うダイナミックな分野として浮上してきました。近年、ペプチドベースの治療薬の進歩により、GLP-1受容体作動薬は2型糖尿病や肥満症などの疾患に対する有効性が実証され、脚光を浴びています。GLP-1受容体作動薬市場は、厳密な研究と確かな臨床結果が融合した市場であり、技術革新、戦略的提携、患者中心の治療への関心の高まりが特徴となっています。

慢性代謝性疾患の発症は、血糖値を管理するだけでなく、体重減少や心血管サポートなどのその他の特典も提供する治療に対する需要を喚起しています。その結果、製薬業界の利害関係者はこの分野への投資を拡大し、従来の治療パラダイムの限界を押し広げています。

さらに、規制の変化や償還の枠組みの進化が果たす役割も軽視できず、これらの要因は市場参入や競合力学を絶えず再構築しています。これらの要素が相互に作用し合うことで、より個別化され、より効果的で、よりアクセスしやすいGLP-1受容体作動薬のコレクションが治療戦略を支配する未来が示唆されます。この進化するシナリオにおいて、基本的な動向、セグメンテーション、地域的需要、主要な業界プレイヤーを理解することは、この高ステークスの市場をナビゲートし、影響を与えようとする者にとって不可欠です。

GLP-1受容体作動薬市場の変革

GLP-1受容体作動薬を取り巻く環境は、科学的、臨床的、市場的に様々な要因によって大きく変化しています。近年、先進的な製剤技術や細胞レベルでの薬物相互作用の深い理解に後押しされ、革新的な調査によって治療基準が再定義されつつあります。新しい臨床試験のパラダイムは、患者の転帰を改善しただけでなく、既存の治療法の適応を拡大し、より広範な疾患管理プロトコールに統合しました。

こうした変化の背後にある重要な力は、医薬品とデジタルヘルスソリューションの統合です。患者モニタリングの強化、データ分析、リアルタイムのフィードバックメカニズムにより、治療に対するより総合的なアプローチが促進されています。こうした技術的進歩は、単に有効性の向上にとどまらず、治療アドヒアランスや患者エンゲージメントの管理方法にも変革をもたらしつつあります。

同時に、様々な地域の規制当局が、安全性に妥協することなく承認プロセスを合理化し、新規GLP-1治療薬の市場参入を加速させています。研究機関、バイオテクノロジー企業、製薬大手間の戦略的提携も、学際的な知識が治療イノベーションを推進する環境を醸成しています。その結果、患者に優しく、経済的にも実行可能な治療法が急速に進化しています。

業界の競争が激化する中、各社は研究開発戦略を洗練させ、臨床試験デザインを再調整し、的を絞ったマーケティングキャンペーンを展開しています。意思決定プロセスには、現実のエビデンスと高度な分析を取り入れることが、今や基本となっています。このような変革的なシフトは、次世代の治療ソリューションだけでなく、患者ケアやコスト効率のニュアンスにより敏感に反応する市場環境も整えつつあります。

GLP-1受容体作動薬市場の主なセグメンテーション洞察

GLP-1受容体作動薬市場は、市場の動向と機会に関する重要な洞察を提供する複数の次元に沿って複雑にセグメント化されています。薬剤クラス別に深く分析すると、市場はデュラグルチド、リラグルチド、セマグルチドなどの重要な成分にわたって調査されており、それぞれがユニークな臨床的・薬理学的プロファイルを示し、多様な患者集団への採用を促進していることがわかります。さらに、薬剤の種類から得られた洞察によれば、長時間作用型作動薬と短時間作用型作動薬の両方が、特定の患者のニーズに対応する上で重要な役割を果たしており、長時間作用型製剤は持続的な治療効果をもたらし、短時間作用型製剤は急性期に迅速な作用をもたらします。

投与経路は、経口剤と非経口剤の両方に焦点を当てた分析により、市場の多様性をさらに示しています。このデュアルモード研究は、患者の嗜好や異なる投与方法に関連するロジスティクスのニュアンスの理解をサポートします。さらに、用途別のセグメンテーションでは、心血管疾患、糖尿病管理、体重管理におけるGLP-1受容体作動薬の役割が包括的な治療プロトコルを推進する上で重要であることが強調されています。これらの用途は、合併症を管理し、患者の全体的な健康アウトカムを向上させる上で極めて重要です。

さらに、流通チャネル分析では、病院薬局、オンライン薬局、小売薬局などのチャネルから得られた知見から、市場に合わせたアプローチの重要性が強調されています。このセグメンテーションにより、利害関係者は患者が医薬品にアクセスする多様な経路を理解することができ、市場浸透を最適化するための的を絞った戦略が可能になります。治療クラスから流通チャネルまで、各セグメンテーションパラメータは、GLP-1受容体作動薬市場に内在する機会と課題をきめ細かく理解し、戦略的意思決定と資源配分の指針となります。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 糖尿病と肥満の有病率が世界的に上昇
    • 世界人口の高齢化と生活習慣病への意識の高まり
    • 政府の取り組みとヘルスケア費の増加
  • 抑制要因
    • 治療費の高騰と副作用
  • 機会
    • 患者の服薬遵守と利便性を向上させるドラッグデリバリーシステムの進歩
    • 研究開発を加速するための戦略的協力と提携
  • 課題
    • 研究開発を加速するための戦略的協力と提携
• 市場セグメンテーション分析
  • 薬剤の種類：患者のコンプライアンス要因と、より広範な慢性疾患治療モデルへの適合性により、長時間作用型アゴニストの採用が増加しています。
  • 応用：血糖コントロールを改善する抗糖尿病薬としてのGLP-1受容体作動薬の嗜好拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 GLP-1受容体作動薬市場薬剤クラス別

• デュラグルチド
• リラグルチド
• セマグルチド

第7章 GLP-1受容体作動薬市場薬剤の種類別

• 長時間作用型アゴニスト
• 短時間作用型アゴニスト

第8章 GLP-1受容体作動薬市場：投与経路別

• オーラル
• 非経口

第9章 GLP-1受容体作動薬市場：用途別

• 心臓血管の健康
• 糖尿病管理
• 体重管理

第10章 GLP-1受容体作動薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 南北アメリカのGLP-1受容体作動薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のGLP-1受容体作動薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのGLP-1受容体作動薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Amgen Inc.
• AstraZeneca Inc.
• Bachem Group
• Biopharma PEG
• Boehringer Ingelheim International GmbH
• Calibrate Health, Inc.
• Cleveland Clinic
• Daiichi Sankyo Company, Limited
• Diabetes UK
• Eli Lilly and Company
• GenScript
• GlaxoSmithKline plc
• GoodRx, Inc.
• Hanmi Pharm.Co.,Ltd.
• Innovent Biologics, Inc.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Merck & Co., Inc.
• Novo Nordisk A/S
• Oramed Pharmaceuticals Inc.
• Patsnap（UK）Ltd.
• Pfizer Inc
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Twist Bioscience Corporation
• WebMD LLC.

LIST OF FIGURES

• FIGURE 1. GLP-1 RECEPTOR AGONIST MARKET MULTI-CURRENCY
• FIGURE 2. GLP-1 RECEPTOR AGONIST MARKET MULTI-LANGUAGE
• FIGURE 3. GLP-1 RECEPTOR AGONIST MARKET RESEARCH PROCESS
• FIGURE 4. GLP-1 RECEPTOR AGONIST MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. GLP-1 RECEPTOR AGONIST MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. GLP-1 RECEPTOR AGONIST MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. GLP-1 RECEPTOR AGONIST MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GLP-1 RECEPTOR AGONIST MARKET DYNAMICS
• TABLE 7. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY LONG-ACTING AGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY SHORT-ACTING AGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY WEIGHT MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 42. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. CANADA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 70. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. CHINA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 75. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. INDIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 129. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 159. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 160. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 161. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 162. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. ITALY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 174. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 180. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 181. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 182. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. POLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 184. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 185. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 186. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. QATAR GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 204. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 209. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 214. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 219. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 224. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM GLP-1 RECEPTOR AGONIST MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 234. GLP-1 RECEPTOR AGONIST MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 235. GLP-1 RECEPTOR AGONIST MARKET, FPNV POSITIONING MATRIX, 2024

The GLP-1 Receptor Agonist Market was valued at USD 40.31 billion in 2024 and is projected to grow to USD 45.59 billion in 2025, with a CAGR of 13.36%, reaching USD 85.55 billion by 2030.

The GLP-1 receptor agonist market has emerged as a dynamic field where scientific innovation meets a rapidly evolving healthcare landscape. In recent years, advancements in peptide-based therapies have propelled GLP-1 receptor agonists into the spotlight due to their proven efficacy in managing conditions such as type 2 diabetes and obesity. This market represents a convergence of rigorous research and robust clinical outcomes, and it is characterized by a blend of technological innovation, strategic collaborations, and an increasing focus on patient-centric treatments.

The onset of chronic metabolic diseases has catalyzed the demand for treatments that not only manage blood glucose levels but also offer additional benefits such as weight reduction and cardiovascular support. As a result, stakeholders across the pharmaceutical industry have escalated their investments in this sector, pushing the boundaries of traditional treatment paradigms.

Moreover, the role of regulatory shifts and evolving reimbursement frameworks cannot be understated, as these factors continuously reshape market access and competitive dynamics. The interplay of these dimensions suggests a future where more personalized, effective, and accessible collections of GLP-1 receptor agonists dominate therapeutic strategies. In this evolving scenario, understanding the underlying trends, segmentation, regional demands, and key industry players is essential for anyone seeking to navigate or influence this high-stakes market.

Transformative Shifts in the GLP-1 Receptor Agonist Landscape

The landscape of GLP-1 receptor agonists is witnessing profound transformations owing to a range of scientific, clinical, and market-driven forces. Recent years have seen innovative research redefining therapy standards, driven by advanced formulation techniques and a deeper understanding of drug interactions at the cellular level. New clinical trial paradigms have not only improved patient outcomes but have also expanded the indications for existing therapies, integrating them into broader disease management protocols.

A critical force behind these changes is the integration of digital health solutions alongside pharmaceuticals. Enhanced patient monitoring, data analytics, and real-time feedback mechanisms have facilitated a more holistic approach to therapy. These technical advancements are not just limited to improving efficacy but are also transforming how treatment adherence and patient engagement are managed.

Simultaneously, regulatory bodies across various geographies have streamlined approval processes without compromising on safety, thereby accelerating market entry for new GLP-1 therapies. Strategic alliances between research institutions, biotechnology firms, and pharmaceutical giants are also fostering an environment where cross-disciplinary knowledge propels therapeutic innovation. This has resulted in the rapid evolution of treatment modalities that are both patient-friendly and economically viable.

As the industry becomes increasingly competitive, companies are refining their research and development strategies, recalibrating clinical trial designs, and deploying targeted marketing campaigns. The incorporation of real-world evidence and advanced analytics in decision-making processes is now fundamental. These transformative shifts are setting the stage not only for next-generation therapeutic solutions but also for a market landscape that is more responsive to the nuances of patient care and cost efficiency.

Key Segmentation Insights in the GLP-1 Receptor Agonist Market

The GLP-1 receptor agonist market is intricately segmented along multiple dimensions that provide vital insight into market behavior and opportunities. A deep analysis based on drug class reveals that the market is studied across critical components such as Dulaglutide, Liraglutide, and Semaglutide, each exhibiting unique clinical and pharmacological profiles that drive their adoption in diverse patient populations. Furthermore, insights derived from studying drug type indicate that both Long-Acting Agonists and Short-Acting Agonists play a significant role in addressing specific patient needs, where long-acting formulations offer sustained therapeutic benefits and short-acting ones provide rapid action during acute phases.

The route of administration further illustrates the market's versatility with analytical focus on both Oral and Parenteral forms. This dual-mode study supports an understanding of patient preferences and the logistical nuances associated with different delivery methods. In addition, the application-based segmentation underscores the importance of GLP-1 receptor agonists, with their roles in Cardiovascular Health, Diabetes Management, and Weight Management driving comprehensive treatment protocols. These applications are critical in managing comorbidities and enhancing overall patient health outcomes.

Moreover, the distribution channel analysis highlights the importance of tailored market approaches, as insights are drawn from channels including Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. This segmentation allows stakeholders to understand the varied paths through which patients access medications and enables targeted strategies to optimize market penetration. Each segmentation parameter, from therapeutic class to distribution channel, offers a granular understanding of the opportunities and challenges inherent in the GLP-1 receptor agonist market, thereby guiding strategic decision-making and resource allocation.

Based on Drug Class, market is studied across Dulaglutide, Liraglutide, and Semaglutide.

Based on Drug Type, market is studied across Long-Acting Agonists and Short-Acting Agonists.

Based on Route of Administration, market is studied across Oral and Parenteral.

Based on Application, market is studied across Cardiovascular Health, Diabetes Management, and Weight Management.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Key Regional Dynamics Shaping the Market

Regional dynamics play an instrumental role in shaping market outcomes for GLP-1 receptor agonists. In the Americas, strong healthcare infrastructure combined with high rates of metabolic disorders has led to significant investments in treatment advancements and patient education programs. The regulatory environment in this region supports accelerated drug approvals, fostering a competitive yet nurturing ecosystem for innovator and biosimilar approaches alike.

In Europe, the Middle East, and Africa, a unique mix of established and emerging healthcare markets is evident. These regions benefit from robust research frameworks, strong governmental support for innovative healthcare solutions, and rising awareness regarding chronic disease management. Strategic collaborations and public-private partnerships have spurred local innovations and facilitated improved accessibility to advanced GLP-1 therapies.

Across the Asia-Pacific, rapid urbanization, increasing healthcare demands, and evolving lifestyle trends have spurred a burgeoning market for GLP-1 receptor agonists. Emerging economies in this region are increasingly prioritizing healthcare reforms and investing in infrastructure that allows for advanced diagnostic and therapeutic interventions. The diverse regional market dynamics not only reflect varied healthcare ecosystems but also highlight the multifaceted challenges and opportunities that companies must navigate to achieve sustainable growth across different geographies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights into Key Industry Players

The competitive landscape of the GLP-1 receptor agonist market is enriched by the active participation of multiple high-caliber companies, each contributing unique strengths to overall market innovation and patient care. Leading organizations such as Amgen Inc. and AstraZeneca Inc. have demonstrated unwavering commitment to research excellence and robust clinical applications. Their substantial investments in R&D have paved the way for significant leaps in the formulation and delivery of GLP-1 receptor agonists.

Notably, organizations like Bachem Group and Biopharma PEG have carved niches in manufacturing and bioconjugation technologies, supporting the complex production requirements intrinsic to peptide-based therapies. Esteemed institutions including Boehringer Ingelheim International GmbH, Calibrate Health, Inc., and the Cleveland Clinic have fostered multidisciplinary collaborations that reinforce the clinical credibility of therapeutic applications.

The presence of companies such as Daiichi Sankyo Company, Limited and Diabetes UK further underscores the market's commitment to patient-centric innovations, while Eli Lilly and Company and GenScript continue to lead in biotherapeutic advances. Well-established players like GlaxoSmithKline plc and GoodRx, Inc. ensure wide market reach and robust supply chain strategies, complementing the innovative strides made by Hanmi Pharm.Co.,Ltd. and Innovent Biologics, Inc.

The pharmaceutical landscape is further diversified by regional and global influencers including Jiangsu Hengrui Pharmaceuticals Co., Ltd., Merck & Co., Inc., and Novo Nordisk A/S, who bring extensive clinical expertise to the table. Oramed Pharmaceuticals Inc. and Patsnap (UK) Ltd. add valuable perspectives by pioneering novel delivery systems and market intelligence analytics. The contributions of Pfizer Inc., Sanofi SA, and Sun Pharmaceutical Industries Ltd. are instrumental in sustaining competitive dynamics, while Twist Bioscience Corporation and WebMD LLC offer technological insights that assist in bridging clinical practice with patient engagement. Collectively, these companies embellish the market with a rich tapestry of research, innovation, and strategic vision, fostering an environment where groundbreaking therapies can thrive.

The report delves into recent significant developments in the GLP-1 Receptor Agonist Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca Inc., Bachem Group, Biopharma PEG, Boehringer Ingelheim International GmbH, Calibrate Health, Inc., Cleveland Clinic, Daiichi Sankyo Company, Limited, Diabetes UK, Eli Lilly and Company, GenScript, GlaxoSmithKline plc, GoodRx, Inc., Hanmi Pharm.Co.,Ltd., Innovent Biologics, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Merck & Co., Inc., Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Patsnap (UK) Ltd., Pfizer Inc, Sanofi SA, Sun Pharmaceutical Industries Ltd., Twist Bioscience Corporation, and WebMD LLC.. Actionable Recommendations for Industry Leaders

To capitalize on the multifaceted opportunities within the GLP-1 receptor agonist market, industry leaders must activate an agile, data-driven strategy that encompasses both innovation and market expansion. First, prioritizing substantial investments in research and development is critical. Leaders should channel resources into enhancing clinical trial designs and engaging in cross-functional collaborations that bridge the gap between laboratory breakthroughs and real-world patient outcomes.

In addition, it is advisable for companies to conduct deep-dive analyses into market segmentation to identify under-served patient cohorts and emerging therapeutic niches. Leveraging insights from the diverse segmentation like drug classes, drug types, and routes of administration can reveal hidden efficiencies and patient adherence trends that ultimately drive commercial success. Furthermore, expanding distribution strategies by integrating digital channels with traditional supply networks will enable broader and more efficient market penetration.

Industry stakeholders should also take an active role in influencing policy reforms and regulatory frameworks. Engaging with regional regulators and participating in public-private partnerships can lead to more favorable market conditions and smoother pathways for product introductions. Moreover, adopting personalized marketing strategies that address the varied cultural and economic backgrounds of patient populations can elevate brand trust and loyalty.

Finally, building a robust ecosystem that synergizes innovation, patient support, and strategic alliances will be pivotal. Companies should invest in comprehensive market intelligence platforms that provide real-time data and predictive analytics, ensuring that every strategic decision is backed by actionable insights. This multi-pronged approach will not only ensure sustained market leadership but also empower companies to navigate the complex interplay of science, technology, and patient care with confidence.

Conclusion and Market Outlook

The GLP-1 receptor agonist market stands at a transformative juncture where impressive scientific advancements and dynamic market forces converge to redefine patient treatment paradigms. A critical review of market trends reveals that significant opportunities lie in the sectors of personalized medicine, innovative drug delivery systems, and enhanced patient care protocols. The integration of advanced technological solutions with traditional pharmaceutical research has set the stage for sustained growth, driven by dynamic clinical research and robust regulatory support.

As the market continues to evolve, the dual emphasis on improving efficacy and addressing real-world therapeutic challenges will serve as the bedrock for competitive differentiation. The interplay between demand-side pressures from chronic disease prevalence and supply-side innovations creates an environment where agility, collaboration, and a relentless focus on patient outcomes are indispensable. The comprehensive segmentation and regional analyses provide a framework that not only highlights existing market strengths but also underscores areas of untapped potential.

In summary, the future trajectory of the GLP-1 receptor agonist landscape is promising, with key players and strategic initiatives collaborating to overcome challenges and expand reach. By leveraging a nuanced understanding of market segmentation, regional variances, and competitive dynamics, stakeholders are well-positioned to harness new growth avenues and set a benchmark in therapeutic excellence. The commitment to continuous innovation and strategic partnerships will undeniably shape the future of metabolic disease management and related therapeutic disciplines.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Global rise in the prevalence of diabetes and obesity
    • 5.1.1.2. Aging global population and growing awareness about lifestyle diseases
    • 5.1.1.3. Increasing government initiatives and healthcare expenditure
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of treatment and adverse side effects
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in drug delivery systems to improve patient adherence and convenience
    • 5.1.3.2. Strategic collaborations and alliances to accelerate the research and development
  • 5.1.4. Challenges
    • 5.1.4.1. Strategic collaborations and alliances to accelerate the research and development
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Growing adoption of long-acting agonists due to patient compliance factors and their fitting into a broader chronic care model
  • 5.2.2. Application: Expanding preferences of GLP-1 receptor agonists as anti-diabetic medications improving glycemic control
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. GLP-1 Receptor Agonist Market, by Drug Class

• 6.1. Introduction
• 6.2. Dulaglutide
• 6.3. Liraglutide
• 6.4. Semaglutide

7. GLP-1 Receptor Agonist Market, by Drug Type

• 7.1. Introduction
• 7.2. Long-Acting Agonists
• 7.3. Short-Acting Agonists

8. GLP-1 Receptor Agonist Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral

9. GLP-1 Receptor Agonist Market, by Application

• 9.1. Introduction
• 9.2. Cardiovascular Health
• 9.3. Diabetes Management
• 9.4. Weight Management

10. GLP-1 Receptor Agonist Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Americas GLP-1 Receptor Agonist Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific GLP-1 Receptor Agonist Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa GLP-1 Receptor Agonist Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Novo Nordisk collaborate with Ascendis for innovation in monthly GLP-1 receptor agonists
  • 14.3.2. Pfizer advances the development of oral GLP-1 receptor agonist for Type 2 diabetes
  • 14.3.3. Teva Pharmaceuticals improves diabetes care by launching the first generic GLP-1 receptor agonist in the U.S.
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen Inc.
• 2. AstraZeneca Inc.
• 3. Bachem Group
• 4. Biopharma PEG
• 5. Boehringer Ingelheim International GmbH
• 6. Calibrate Health, Inc.
• 7. Cleveland Clinic
• 8. Daiichi Sankyo Company, Limited
• 9. Diabetes UK
• 10. Eli Lilly and Company
• 11. GenScript
• 12. GlaxoSmithKline plc
• 13. GoodRx, Inc.
• 14. Hanmi Pharm.Co.,Ltd.
• 15. Innovent Biologics, Inc.
• 16. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• 17. Merck & Co., Inc.
• 18. Novo Nordisk A/S
• 19. Oramed Pharmaceuticals Inc.
• 20. Patsnap (UK) Ltd.
• 21. Pfizer Inc
• 22. Sanofi SA
• 23. Sun Pharmaceutical Industries Ltd.
• 24. Twist Bioscience Corporation
• 25. WebMD LLC.